Tue, Jul 22, 2014, 12:01 PM EDT - U.S. Markets close in 3 hrs 59 mins

Recent

% | $
Click the to save as a favorite.

Celldex Therapeutics, Inc. Message Board

  • mabiotech mabiotech Feb 21, 2013 10:23 PM Flag

    RSI 87 = outrageously high, almost guaranteed sharp pullback on Friday

    Trade it, don't fall in love with it.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I noticed that too. The longs are too self-assured. CLDX has gotten way, way, WAY overbought. Irrational buying taking place into the close. I bet it falls on Friday too. It shouldn't have gotten back over $9 because it's so overbought.

      • 2 Replies to jjgrabowskijr
      • 'way, way, WAY overbought'? In my view: the contrary!

        MITI was bought for 1.1 bn$ a year ago with its lead project, blinatumomab, in phase III at the time. ARIA went all the way into the 3 bn$ market cap when ponatinib was still in phase III and above 4 bn$ market cap after filing (lost 20%, of course, after the final label became known). Both of these products for much smaller target markets then CLDX' lead project in phase III (GBM) or phase III-ready (mBC), plus CLDX' other pipeline is more diverse than these comparator co's. Market cap could go 3 to 5x or more within 12 to 18 months for CLDX.

        Sentiment: Strong Buy

      • We all know the pipeline is worth more than 600 million dollars, the chart has had these moves on the for years not days or weeks or months. It had 7.63, 9.07 and 11 written all over it. CLDX is worth 15 easily coming through research phases. It is not always the price but the share count and volume activity, I would make that mistake for years not understanding share count and price objective along with revenue growth and margins that is what makes electronic technology so hard to trade and biotech so great once they begin to move.

 
CLDX
12.751-0.249(-1.92%)12:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.